Pirfenidone CAS 53179-13-8: A Pharma Grade Anti-Fibrosis Agent for Idiopathic Pulmonary Fibrosis
Discover the therapeutic potential of Pirfenidone, a key anti-fibrotic agent vital for managing Idiopathic Pulmonary Fibrosis (IPF).
Get a Quote & SampleProduct Core Value
Pirfenidone Anti-fibrosis Powder
Pirfenidone (CAS 53179-13-8) is a critical pharmaceutical grade powder designed to combat fibrosis. Its primary application lies in the treatment of Idiopathic Pulmonary Fibrosis (IPF), where it plays a vital role in slowing the progression of lung scarring and function decline. Beyond its antifibrotic properties, Pirfenidone also exhibits anti-inflammatory and antioxidant effects, contributing to the overall mitigation of tissue damage in fibrotic conditions. The compound is known to delay the decline of lung function, thereby improving the quality of life for patients suffering from IPF.
- Understanding the mechanisms of Pirfenidone in fibrosis: Pirfenidone operates by inhibiting fibroblast proliferation and collagen synthesis, key processes in fibrotic diseases.
- Clinical trials for Idiopathic Pulmonary Fibrosis: Extensive research, including Phase III trials like ASCEND, has demonstrated Pirfenidone's efficacy in significantly slowing lung function decline and improving progression-free survival in IPF patients.
- Pirfenidone side effects and management: Common side effects such as photosensitivity and gastrointestinal issues are manageable, with ongoing monitoring by medical professionals being crucial.
- Pharma grade Pirfenidone powder uses: This high-purity powder is suitable for adult patients with IPF and may have potential applications in treating fibrotic conditions in other organs, including the heart and kidneys.
Product Benefits
Delay Lung Function Decline
Pirfenidone is clinically proven to slow the progressive loss of lung function, offering a tangible benefit for patients managing IPF.
Reduce Inflammation
With its anti-inflammatory properties, Pirfenidone helps to mitigate the inflammatory responses contributing to lung fibrosis, supported by research on its impact on cytokines like TNF-α.
Improve Quality of Life
By slowing disease progression and managing symptoms, Pirfenidone contributes to a better quality of life for individuals diagnosed with IPF.
Key Applications
Idiopathic Pulmonary Fibrosis Treatment
The primary application of Pirfenidone is in the treatment of IPF, a progressive lung disease characterized by scarring, supported by numerous clinical trials.
Fibrotic Lung Diseases Management
Evidence suggests Pirfenidone's potential in managing other fibrosing interstitial lung diseases, offering hope for broader therapeutic applications.
Potential Cardiac Applications
Preclinical studies indicate Pirfenidone's antifibrotic effects in cardiac models, suggesting a potential role in treating heart conditions like Heart Failure with Preserved Ejection Fraction (HFpEF).
Antioxidant and Anti-inflammatory Effects
These broader effects contribute to tissue protection and management of inflammatory conditions, making it a versatile pharmaceutical intermediate.
Related Technical Articles & Resources
Why Choose Us?
Leverage our expertise and state-of-the-art infrastructure to accelerate your journey from discovery to commercial success.
Global Experience
With 20 years of R&D, manufacturing, and sales experience, we proudly serve clients across 60 countries and regions worldwide.
Advanced Facilities
Our in-house R&D laboratory, pilot platform, and large-scale production workshop are equipped to meet the audit requirements of global customers.
Seamless Scalability
We facilitate a perfect transition from small-scale lab requirements (grams) to full commercialization (hundreds of tons).